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ABSTRACT
Wehaveinvestigated, inneonates, whether the calcium-sensing receptor (CaR) mediates the effects ofdietary calcium onbone turnover
and/or modulates parathyroid hormone (PTH)–induced bone turnover. Wild-type (WT) pups and pups with targeted deletion of the Pth
(Pth
–/–)geneorofbothPthandCaR(Pth
–/–CaR
–/–)geneswerenursed bydamsonanormalorhigh-calciumdiet.Pupsnursedbydamson
a normal diet received daily injections of vehicle or of PTH(1–34) (80mg/kg) for 2 weeks starting from 1 week of age. In pups receiving
vehicle and fed by dams on a normal diet, trabecular bone volume, osteoblast number, type 1 collagen–positive area, and mineral
apposition rate, as well as the expression of bone-formation-related genes, all were reduced significantly in Pth
–/– pups compared with
WT pups and were decreased even more dramatically in Pth
–/–CaR
–/– pups. These parameters were increased in WT and Pth
–/– pups but
not in Pth
–/–CaR
–/– pups fed by dams on a high-calcium diet compared with pups fed by dams on a normal diet. These parameters also
were increased in WT, Pth
–/–, and Pth
–/–CaR
–/– pups following exogenous PTH treatment; however, the percentage increase was less in
Pth
–/–CaR
–/– pups than in WT and Pth
–/– pups. In vehicle-treated pups fed by dams on either the normal or high-calcium diet and in PTH-
treated pups fed by dams on a normal diet, the number and surfaces of osteoclasts and the ratio of RANKL/OPG were reduced
significantly in Pth
–/– pups and less significantly in Pth
–/–CaR
–/– pups compared with WT pups. These parameters were further reduced
significantly in WT and Pth
–/– pups from dams fed a high-calcium diet but did not decrease significantly in similarly treated Pth
–/–CaR
–/–
pups, and they increased significantly in PTH-treated pups compared with vehicle-treated, genotype-matched pups fed by dams on the
normal diet. These results indicate that in neonates, the CaR mediates alterations in bone turnover in response to changes in dietary
calcium and modulates PTH-stimulated bone turnover.  2011 American Society for Bone and Mineral Research.
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Introduction
T
he calcium-sensing receptor (CaR) plays a central role in
controlling systemic calcium homeostasis, predominately
through its effects on regulation of parathyroid hormone (PTH)
secretion by the parathyroid glands and urinary calcium
excretion by the kidney.
(1-3) Recent evidence clearly has shown
that the CaR is expressed and modulates cell function in a variety
of bone cells, including osteoblasts,
(4-8) stromal cells,
(9) osteo-
clasts,
(6,10,11) and chondrocytes.
(4) Previous studies on cultured
osteoblasts have shown that CaR activation not only stimulates
the proliferation of these cells but also promotes their
differentiation and mineralization. Cellular proliferation and
expression of osteoblast differentiation markers, including Cbfa-
1, alkaline phosphatase (Alp), type 1 collagen, and osteocalcin, and
mineralized nodule formation were increased significantly in rat
calvarial osteoblasts treated with high calcium. Inhibition of the
CaR by NPS 89636 (a CaR antagonist) blocked responses in vitro
to CaR agonists, suggesting that high-calcium-induced osteo-
blastic differentiation was mediated by the CaR.
(5) Abolition of
ORIGINAL ARTICLE J JBMR
Received in original form March 7, 2010; revised form August 23, 2010; accepted November 11, 2010. Published online November 23, 2010.
Address correspondence to: Dengshun Miao, MD, PhD, Laboratory of Reproductive Medicine, Research Center for Bone and Stem Cells, Nanjing Medical University,
Nanjing, Jiangsu, 210029, People’s Republic of China E-mail: dsmiao@njmu.edu.cn
Journal of Bone and Mineral Research, Vol. 26, No. 5, May 2011, pp 1057–1071
DOI: 10.1002/jbmr.300
 2011 American Society for Bone and Mineral Research
1057CaR function by stably transfecting MC3T3-E1 cells with either a
CaR antisense vector or a vector containing the dominant-
negative R185Q variant of the CaR resulted in diminishing ALP
activity, osteocalcin expression, and mineralization in mouse
osteoblastic cells.
(12) More recently, mice with conditional
knockout of the CaR in early committed osteoblasts were
generated by breeding a novel mouse line carrying a CaR gene
allele in which exon 7 had been floxed with transgenic mice
expressing Cre recombinase under the control of a 2.3-kb type 1
collagen promoter.
(13) Smaller, undermineralized skeletons with
significant reductions in bone volume and bone mineral density
(BMD) were observed in the femur and vertebrae from the
conditional knockout mice. This study demonstrated a critical
role for the CaR at early stages of osteoblastic differentiation and
bone development potentially by promoting osteoblast matura-
tion.
Previous studies failed to find a direct role for CaR in mice
homozygous for targeted disruption of exon 5 of the CaR gene,
which encodes a segment of the extracellular domain of this
receptor.
(14,15) These observations may have been confounded
by the severe hyperparathyroidism and accompanying hyper-
calcemia and hypophosphatemia in this animal model. To better
understand the direct effects of the CaR on bone and cartilage
function, correction of hyperparathyroidism is required in this
CaR-deficient mouse model. Therefore, a double-knockout
model was established by ablating the Pth gene in the CaR-
deficient mice
(16,17) to correct the severe hyperparathyroidism,
hypercalcemia, and hypophosphatemia observed in the CaR-
deficient mice. The results of this study showed that elimination
of hyperparathyroidism rescued the mice from the increased
neonatal mortality as well as the rickets-like skeletal abnormality
intheCaR
–/–mice.However,anyessential,nonredundantrolefor
CaR in regulating chondrogenesis or osteogenesis was not
identified based on analysis of the skeleton of this adult double-
knockout model. It is unclear why there are discrepancies
between the findings from the mice with the osteoblastic-
specific knockout of exon 7 of the CaR gene
(13) and those from
mice with conventional global knockout of exon 5 of both the
CaR andPthgenes
(14,16) regarding the physiologic significance of
the CaR in osteoblasts. It is possible, however, that the
alternatively spliced CaR lacking exon 5 that is expressed in
the global exon 5 knockout mice may compensate to some
extent in bone for loss of the full-length CaR.
PTH can stimulate bone formation in adult and aged animals
of either sex and in animals with osteopenia induced by disuse,
denervation, and immobilization.
(18) The anabolic action of PTH
on bone has been validated in humans
(19-21) and its antifracture
efficacy established in postmenopausal osteoporotic women.
(22)
At present, however, the physiologic basis of PTH anabolism
remains unclear.
(23,24) A large body of evidence demonstrates
that sufficient calcium intake augments bone gain during
growth, retards age-related bone loss, and reduces osteoporotic
fracture risk,
(25-27) but the mechanisms underlying the positive
effect of increased calcium intake on bone mass are unknown.
Our recent study indicates that the skeletal anabolic action of
PTH inneonatesresultsnotonly fromitsdirectactionviathePTH
receptor to increase the osteoblast pool but also by an indirect
action mediated through PTH-induced increases in the extra-
cellular calcium concentration.
(28) However, it is unclear whether
the increase in extracellular calcium caused by PTH administra-
tion acts cooperatively with a skeletal anabolic action mediated
via the CaR.
In this study, we attempted to determine whether deletion of
CaR in PTH-deficient mice (1) leads to a skeletal phenotype
distinct from that caused by deletion of Pth alone before
weaning, (2) abolishes skeletal responses to dietary calcium
supplementation, and (3) reduces skeletal responses to
exogenous PTH administration. To explore these issues, we
examined pups from wild-type (WT), Pth
–/–, and Pth
–/–CaR
–/–
mice nursed by dams on a normal calcium diet or on a high-
calcium diet. In addition, we treated some pups nursed by dams
on a normal calcium diet with daily injections of vehicle or of
PTH(1–34) for 2 weeks starting from 1 week of age and assessed
skeletal homeostasis.
Materials and Methods
Derivation of Pth
–/– and Pth
–/–CaR
–/– mice
The derivation of the two parental strains of Pth
–/– mice and
CaR
–/– mice by homologous recombination in embryonic stem
cells was described previously by Miao and colleagues
(29) and Ho
and colleagues,
(15) respectively. Pth
þ/– mice were bred with
CaR
þ/– mice to generate Pth
þ/–CaR
þ/– mice. Pth
þ/–CaR
þ/– mice
were bred among themselves to generate Pth
–/–CaR
–/– pups.
These mice were maintained on a mixed genetic background
with contributions from C57B6, 129/SvJ, and 129/SvEv strains.
The genotypes of the animals were determined by polymerase
chain reaction (PCR).
In vivo experiments
All animal experiments were approval by the Institutional Animal
Care and Use Committee. Mice were maintained in a virus- and
parasite-free barrier facility and exposed to a 12-hour light/dark
cycle. To determine whether PTH and calcium interact in
neonatal calcium and skeletal homeostasis, WT, Pth
–/–,o r
Pth
þ/–CaR
þ/– dams were fed with rodent diets from Harlan
Teklad (Madison, WI, USA) containing either normal levels of
calciumandphosphate(1%Ca,0.6%phosphate)orhigh-calcium
and moderate-phosphate levels (2% Ca and 0.4% phosphate).
Serum biochemistry was not significantly different in the
Pth
þ/–CaR
þ/– mice than in the WT mice. Dietary phosphate
content in the high-calcium diet was reduced moderately to
decrease phosphate absorption and resulting hyperphosphate-
mia and to facilitate increasing the blood calcium concentration
in the hypoparathyroid Pth
–/– and Pth
–/–CaR
–/– mice. The high-
calcium, moderate-phosphate diet was found to normalize
hypocalcemia and hyperphosphatemia in Pth
–/– and Pth
–/–CaR
–/–
mice and is referred to as the high-calcium diet. Litter size was
equalized to 5 to 6 pups per dam to equalize suckling intensity.
On day 7 postpartum, pups nursed by dams on the normal
calcium diet received daily injections of vehicle or of PTH(1–34)
(80mg/kg) for 2 weeks. At the end of experiments, milk of dams
and blood of pups were collected and used for biochemical
analysis, and long bones of pups then were removed for the
analyses described below.
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Milk calcium (milk was diluted 1:100 in distilled water) was
measured with an atomic absorptiometer as described pre-
viously.
(30) Serum calcium and phosphorus levels were deter-
mined by an autoanalyzer (Beckman Synchron 67; Beckman
Coulter, Inc., Fullerton, CA, USA). Urine calcium levels were
determined using the o-cresolphthalein-complexone method
(Sigma-Aldrich, St Louis, MO, USA), urine creatinine was
measured by the colorimetric alkaline picrate method (Sigma
Kit 555, Sigma-Aldrich), and urine calcium/creatinine ratio
was calculated. Milk and serum 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] was measured by RIA (Immuno-Diagnostic
Systems, Bolden, UK), and PTH-related protein (PTHrP) was
measured by a two-site immunoradiometric assay (Immutopics,
San Clemente, CA, USA). Serum PTH was measured using an
ELISA (Immutopics).
Radiography and measurement of BMD
For radiography, tibias were removed and dissected free of soft
tissue, and X-ray images were taken with a Faxitron machine
(Model 805; Faxitron X-Ray Corp., Wheeling, IL, USA) under
constant conditions (22kV, 4-minute exposure) using Kodak X-
Omat TL film (Eastman Kodak Co., Rochester, NY, USA). For
measurement of tibial BMD, a PIXImus densitometer (Lunar
PIXImus Corp., Madison, WI, USA) was used (5-minute image
acquisition with the precision of 1% coefficient of variation for
skeletalBMD). ThePIXImus software automatically calculated the
BMD and recorded the data in Microsoft Excel files (Microsoft
Corp., Redmond, WA, USA).
Micro–computed tomography (mCT)
Tibias obtained from 3-week-old mice were dissected free of soft
tissue, fixed overnight in 70% ethanol, and analyzed by mCT with
a SkyScan 1072 scanner and associated analysis software
(SkyScan, Antwerp, Belgium) as described previously.
(31) Briefly,
image acquisition was performed at 100kV and 98mA with a 0.9-
degree rotation between frames. During scanning, the samples
were enclosed in tightly fitting plastic wrap to prevent
movement and dehydration. Thresholding was applied to the
images to segment the bone from the background. 2D images
were used to generate 3D renderings using the 3D Creator
software supplied with the instrument (SkyScalciumn). The
resolution of the mCT images is 18.2mm.
Quantitative real-time RT-PCR
Reverse-transcription (RT) reactions were performed using the
SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad,
CA, USA) as described previously.
(32) Real-time polymerase
chain reaction (PCR) was performed using a LightCycler system
(Roche Molecular Biochemicals, Indianapolis, IN, USA). The
conditions were 2mL of LightCycler DNA Master SYBR Green I
(Roche), 0.25mM of each 5’ and 3’ primer (Table 1), and 2mLo f
sample and/or H2O to a final volume of 20mL. Samples were
amplified for 35 cycles with a temperature transition rate of
208C/s for all three steps, which were denaturation at 948Cf o r
10seconds, annealing for 5seconds, and extension at 728Cf o r
20seconds. SYBR green fluorescence was measured to
determine the amount of double-stranded DNA. To discrimi-
nate specific from nonspecific cDNA products, a melting curve
was obtained at the end of each run. Products were denatured
at 948C for 30seconds; the temperature then was decreased to
558C for 15seconds and raised slowly from 55 to 948Cu s i n ga
temperature transition rate of 0.188C/s. To determine the
number of copies of target DNA in the samples, purified PCR
fragments of known concentration were serially diluted and
served as external standards for each experiment. Data were
normalized to GAPDH levels.
Histology
Tibias were removed and fixed in 2% paraformaldehyde
containing 0.075M lysine and 0.01M sodium periodate over-
ni ghta t48C and processed as described previously.
(33)Proximal
ends of tibias weredecalcifiedin EDTA-glycerol solution for 5to
7d a y sa t4 8C. Decalcified right tibias were dehydrated and
embedded in paraffin, after which 5-mm sections were cut on a
rotary microtome. The sections were stained with hematoxylin
and eosin (H&E) or histochemically for tartrate-resistant acid
phosphatase (TRACP) activity or immunohistochemically, as
described below. For calcein labeling, mice were injected
intraperitoneally with 10mgc a l c e i np e rg r a mo fb o d yw e i g h t
(C-0875; Sigma) at 8 and 3 days prior to killing, as described
previously.
(34) Left tibiaa were embedded in LR white acrylic
resin (London Resin Co., Ltd., London, UK), and 1-mms e c t i o n s
were viewed and imaged using fluorescence microscopy. The
double-calcein-labeled widths of trabeculae were measured in
the secondary spongiosa of the proximal ends of tibias using
Northern Eclipse image-analysis software Version 6.0 (Empix
Imaging, Inc., Mississauga, Ontario, Canada), and the mineral
apposition rate (MAR) was calculated as the interlabel width/
labeling period. TRACP staining was performed using a
modification of a previously described protocol.
(32) In brief,
Table 1. Real-Time RT–PCR Primers Used with Their Name,
Orientation (S¼Sense; AS¼Antisense), Sequence, Annealing
Temperature (Tm), and Length of Amplicon (bp)
Name S/AS Sequence Tm(8C) bp
Cbfa-1 S GTGACACCGTGTCAGCAAAG 55 356
AS GGAGCACAGGAAGTTGGGAC
Rankl S GGTCGGGCAATTCTGAATT 57 813
AS GGGGAATTACAAAGTGCACCAG
Opg S TGGAGATCGAATTCTGCTTG 57 719
AS TCAAGTGCTTGAGGGCATAC
Alp S CTTGCTGGTGGAAGGAGGCAGG 55 393
AS GGAGCACAGGAAGTTGGGAC
type 1 collagen S TCTCCACTCTTCTAGTTCCT 55 269
AS TTGGGTCATTTCCACATGC
osteocalcin S CAAGTCCCACACAGCAGCTT 55 370
AS AAAGCCGAGCTGCCAGAGTT
GAPDH S GGTCGGTGTGAACGGATTTG 55 508
AS ATGAGCCCTTCCACAATG
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containing 50mM sodium acetate and 40mM sodium tartrate
at pH 5.0. Sections then were incubated for 15minutes at room
temperature in the same buffer containing 2.5mg/mL of
naphthol AS-MX phosphate (Sigma) in dimethylformamide as
substrate and 0.5mg/mL of fast garnet GBC (Sigma) as a color
indicator for the reaction product. After washing with distilled
water, the sections were counterstained with methyl green and
mounted in Kaiser’s glycerol jelly.
Immunohistochemical staining
Immunohistochemical staining for type 1 collagen was per-
formed using affinity-purified goat anti-mouse type 1 collagen
antibody (Southern Biotechnology Associates, Birmingham, AL,
USA) as described previously.
(33) Briefly, dewaxed and rehy-
drated paraffin-embedded sections were incubated with
methanol–hydrogen peroxide (1:10) to block endogenous
peroxidase activity and then washed in Tris-buffered saline
(pH 7.6). The slides then were incubated with the primary
antibody overnight at room temperature. After rinsing with
Tris-buffered saline for 15minutes, tissues were incubated with
secondary antibody (biotinylated goat anti-rabbit IgG or
biotinylated goat anti-mouse IgG; Sigma). Sections then
were washed and incubated with the Vectastain Elite ABC
reagent (Vector Laboratories, Burlington, Ontario, Canada)
for 45minutes. Staining was developed using 3,3-diaminoben-
zidine (2.5mg/mL) followed by counterstaining with Mayer’s
hematoxylin.
Bone marrow cell cultures
Tibiasandfemursof3-week-oldWT,Pth
–/–,andPth
–/–CaR
–/–pubs
fed by dams on the normal diet or the high-calcium diet that
were administrated the exogenous PTH(1–34) were removed
under aseptic conditions, and bone marrow cells were flushed
out with DMEM containing 10% fetal calf serum (FCS), 50mg/mL
of ascorbic acid, 10mM b-glycerophosphate, and 10
 8 M
dexamethasone. Cellswere dispersed byrepeatedpipetting, and
a single-cell suspension was achieved by forceful expulsion of
the cells through a 22-gauge syringe needle. Total bone marrow
cells (10
6) were cultured in 36-cm
2 Petri dishes in 5mL of the
medium described earlier, which was changed every 4 days, and
cultures were maintained for 18 days. At the end of the culture
period, cells were washed with PBS, fixed with paraformalde-
hyde/lysine/periodate fixative, and stained with methyl blue or
cytochemically for alkaline phosphatase. After staining, the
numbers of total colony-forming units fibroblastic (CFU-F) and
ALP
þ CFU-F were counted manually or by computer-assisted
image analysis.
MAPK assay
The second-passaged bone marrow mesenchymal stem cells
from 2-week-old WT or CaR
–/– mice were cultured with DMEM
containing 10% FCS, 50mg/mL of ascorbic acid, 10mM b-
glycerophosphate, and 10
 8 M dexamethasone until confluence
and were transferred into serum-free DMEM/F12 calcium-
deficient medium (Sigma) overnight. These cells then were
treated with various reagents as described in the figure legends.
After treatment,cells werewashed inPBS (20mMNaH2PO4,0.9%
NaCl, pH 7.4) and lysed for 20minutes with lysis buffer (20mM
Tris-Cl, pH 7.4, 150mM NaCl, 0.1% Nonidet P-40, 1% glycerol,
0.2mMsodiumvanadate,andaproteasemixturetablet/10mLof
buffer). The samples were collected and microcentrifuged at
14,000rpm for 5minutes, and the supernatants were collected,
assayed for protein, and prepared for Western blot analysis with
antibody against the active phosphorylated form of mitogen-
activated protein kinase (MAPK).
(35) Membranes were stripped
and reprobed with polyclonal antibodies against MAPK (ERK-1
and ERK-2).
Western blot analysis
Proteins were extracted from the duodenum of 2-week-old WT
or CaR
–/– mice and quantitated by a kit (Bio-Rad, Mississauga,
Ontario, Canada). In total, 30mg of protein samples was
fractionated by SDS-PAGE and transferred to nitrocellulose
membranes. Immunoblotting was carried out as described
previously
(36) using TRPV5 (ECaC1), calbindin-D28K, calbindin-
D9K,a n dt h eN a
þ/Ca
2þ exchanger (NCX1) (Swant, Bellinzona,
Switzerland) and b-tubulin (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Bands were visualized using ECL
chemiluminescence (Amersham, Piscataway, NJ, USA) and
quantitated by Scion Image Beta 4.02 (Scion Corporation,
Frederick, MD, USA).
Computer-assisted image analysis
After H&E staining or histochemical or immunohistochemical
staining of sections from six mice of each genotype, images of
fields were photographed with a Sony (Tokyo, Japan) digital
camera. Images of micrographs from single sections
were digitally recorded using a rectangular template, and
recordings were processed and analyzed using Northern Eclipse
image-analysis software (Empix Imaging Inc.), as described
previously.
(32–34)
Statistical analysis
Data from image analysis are presented as means SEM.
Statistical comparisons were made using a two-way ANOVA,
with p<.05 being considered significant.
Results
Effect of dietary calcium on milk calcium content and
calcium-regulating hormones in milk
To determine whether dietary calcium affects milk calcium
content and calcium-regulating hormones, milk calcium,
1,25(OH)2D3, and PTHrP levels were examined in lactating
Pth
þ/–CaR
þ/–damsfedeitherthenormaldietorthehigh-calcium
diet.Thehigh-calciumdietincreasedmilkcalciumanddecreased
PTHrP and 1,25(OH)2D3 levels (Fig. 1A–C) but did not affect milk
protein concentrations (Fig. 1D).
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calcium, phosphorus, PTH, and 1,25(OH)2D3 in Pth
–/– and
Pth
–/–CaR
–/– pups
To determine whether maternal dietary calcium and exogenous
PTH affect mineral homeostasis in the suckling pups,
serum calcium, phosphorus, PTH, and 1,25(OH)2D3 levels were
measured in 3-week-old pups fed by Pth
þ/–CaR
þ/– dams on
either the normal diet or the high-calcium diet or administrated
exogenous PTH. Serum calcium levels were decreased in Pth
–/–
and Pth
–/–CaR
–/– pups fed by Pth
þ/–CaR
þ/– dams on either the
normaldiet or the high-calcium diet or administrated exogenous
PTH and were decreased more dramatically in Pth
–/–CaR
–/– pups
fed by Pth
þ/–CaR
þ/– dams on the high-calcium diet or
Fig. 1. Effect of dietary calcium on milk calcium content and calcium-regulating hormones in dams and on serum calcium, phosphorus, PTH, and
1,25(OH)2D3 levels in Pth
–/– and Pth
–/–CaR
–/– pups. (A) Milk calcium, (B) PTHrP, (C) 1,25(OH)2D3, and (D) protein concentrations were determined in the
samples from Pth
þ/–CaR
þ/– dams on day 14 of lactation on the normal diet (Normal Ca) or the high-calcium diet (High Ca) as described in ‘‘Materials and
Methods.’’ (E) Serum calcium, ( F) phosphorus, (G) PTH, and (H) 1,25(OH)2D3 levels were determined in samples from 3-week-old WT, Pth
–/– (Pth KO), and
Pth
–/–CaR
–/– (DKO) pups that were fed by dams on the normal diet or the high-calcium diet or were administered exogenous PTH(1–34). Each value is the
mean SEM of determinations in 5 pups of each genotype.
 p<.05;
  p<.01;
   p<.001 compared with WT littermates of the same group;
~p<.05;
~~p<.01;
~~~p<.001 compared with Pth
–/– littermates of the same group;
#p<.05;
##p<.01;
###p<.001 compared with the genotype-matched pups
fed by dams on the normal diet.
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were still elevated relative to WT mice in both mutants when fed
by mothers on either the normal diet or the high-calcium diet
and were reduced further in the genotype-matched pups fed by
dams on the high-calcium diet compared with pups fed by dams
on the normal diet (Fig. 1F). Serum phosphorus levels were
normalizedbyexogenousPTHtreatmentofbothmutantanimals
(Fig. 1F). Serum PTH levels in WT pups were decreased when the
dams were on the high-calcium diet. Administration of PTH to
pupsincreasedPTH levelsinWTpupsfedbydamsonthe normal
diet. Basal serum PTH levels in Pth
–/– and Pth
–/–CaR
–/– pups were
undetectable (Fig. 1G). Although exogenous PTH administration
increased serum PTH levels in Pth
–/– and Pth
–/–CaR
–/– pups, the
levels were significantly lower than in their WT littermates
(Fig. 1G). Serum 1,25(OH)2D3 levels were reduced in Pth
–/– pups
and were even more reduced in Pth
–/–CaR
–/– pups fed by dams
on the normal diet. Feeding dams a high-calcium diet decreased
serum 1,25(OH)2D3 levels significantly in WT and Pth
–/– pups but
insignificantly in Pth
–/–CaR
–/– pups compared with genotype-
matched pups from dams fed the normal diet. PTH increased
serum 1,25(OH)2D3 levels in all WT, Pth
–/–, and PTH
–/–CaR
–/– pups,
but the percentage increase was less in Pth
–/–CaR
–/– pups than in
the other two genotypes (Fig. 1H).
Effects of dietary calcium and exogenous PTH on
bone growth, BMD, and bone volume in Pth
–/– and
Pth
–/–CaR
–/– pups
To determine whether CaR deficiency influences the effects of
dietarycalciumandexogenousPTHonbonegrowthandBMD,3-
week-old pups were fed by Pth
þ/–CaR
þ/– dams that received
either the normal or the high-calcium diet, or pups were
administrated exogenous PTH. Tibias then were examined by
radiography (Fig. 2A), tibia lengths were measured (Fig. 2B), and
BMD was determined using a PIXImus densitometer (Fig. 2C)i n
the 3-week-old pups.
Pth
–/– pups fed by dams receiving either a normal or a high-
calcium diet had a significant reduction in bone length and BMD
compared with WT pups. The reduction was more severe in
Pth
–/–CaR
–/– pups. Administering the high-calcium diet to dams
increased the length and BMD in WT and Pth
–/– pups but not in
Pth
–/–CaR
–/– pups compared with those on the normal calcium
diet. Two weeks of PTH treatment increased tibial length and
BMD in all WT, Pth
–/–, and Pth
–/–CaR
–/– pups, but the percentage
increase was less in Pth
–/–CaR
–/– pups than in the other two
genotypes. The percentage increases in bone length and BMD
were greater in PTH-treated pups than in pups fed by dams on a
high-calcium diet in both WT and Pth
–/– pups (Fig. 2A–C). To
determine whether CaR deficiency modifies the effects of dietary
calcium and exogenous PTH on bone volume, the trabecular
bone volume was assessed by mCT (Fig. 2D) and histomorpho-
metric analysis (Fig. 2E) in the proximal ends of tibias from mice
treated as described earlier. Consistent with the changes in bone
growth and BMD, Pth
–/– pups fed by dams on either the normal
or the high-calcium diet had reduced trabecular bone volume
compared with WT pups. Bone volume was decreased further in
Pth
–/–CaR
–/– pups. The bone volume was increased in WT and
Pth
–/– pups but not in Pth
–/–CaR
–/– pups fed by dams on a high-
calcium diet compared with genotype-matched pups fed by
dams on a normal calcium diet. PTH treatment increased the
bone volume in all three types of pups, but the increase was
smaller in Pth
–/–CaR
–/– pups than in WT and Pth
–/– pups. The
percentage increase in bone volume was higher in PTH-treated
pupsthaninpupsfedbydamsonahigh-calciumdietinbothWT
and Pth
–/– pups (Figs. 2D, E).
Effects of dietary calcium and exogenous PTH on
osteoblastic bone formation in Pth
–/– and
Pth
–/–CaR
–/– pups
To determine whether or not alterations of trabecular bone
volume in Pth
–/– and Pth
–/–CaR
–/– pups are associated with
changes in osteoblast function, bone-formation parameters
were assessed bystaining withH&E(Fig. 3A), immunostainingfor
type 1 collagen (Fig. 3B), double calcein labeling (Fig. 3C) and
histomorphometric analysis forosteoblast number (Fig. 3D), type
1 positive area (Fig. 3E), and mineral apposition rate (MAR;
Fig. 3F). Pth
–/– pups fed by dams on the normal diet displayed a
significantly reduced osteoblast number, type 1 collagen
immunopositive area, and MAR compared with WT pups, and
these parameters were decreased further in Pth
–/–CaR
–/– pups.
These bone-formation parameters were increased in WT and
Pth
–/–pupsbutnotinPth
–/–CaR
–/–pupsfedbydamsonthehigh-
calcium diet compared with the pups fed by dams on the normal
calcium diet. PTH treatment for 2 weeks increased bone
formation in WT and Pth
–/– pups and Pth
–/–CaR
–/– pups to a
lesser extent. Exogenous PTH had a greater stimulatory effect on
bone formation than in the pups fed by dams on the high-
calcium diet in both WT and Pth
–/– pups (Fig. 3A–F). We also
assessed whether these alterations of osteoblastic bone
formationwereassociatedwithsimilarchangesintheexpression
of several osteoblastic genes. The expression levels of Cbfa-1
(Fig. 4A), Alp (Fig. 4B), type 1 collagen (Fig. 4C), and osteocalcin
(Fig. 4D) were examined by real-time RT-PCR. The alterations in
the expression of transcripts for Cbfa-1, Alp, type 1 collagen, and
osteocalcin, as assessed by real-time RT-PCR, were consistent
with the alterations observed by histomorphometry.
Effects of dietary calcium and exogenous PTH on
osteoprogenitor commitment in Pth
–/– and
Pth
–/–CaR
–/– pups
To investigate whether the reduction in osteoblast numbers in
Pth
–/– and Pth
–/–CaR
–/– pups is due to impaired commitment of
bone marrow mesenchymal stem cells (MSCs) into osteogenic
cells, colony-forming assays were performed using bone marrow
stromal cells from these animals. Consistent with the bone-
formation data, the total number of colony-forming units
fibroblastic (CFU-F) and ALP
þ CFU-F (CFU-FAP) in bones from
Pth
–/–pupsfedbydamsoneitherthenormalorthehigh-calcium
diet were reduced significantly compared with WT pups, with a
further decrease in Pth
–/–CaR
–/– pups (Fig. 5). The high-calcium
diet increased the numbers of CFU-F and CFU-Fap in WT and
Pth
–/– pups but not in Pth
–/–CaR
–/– pups. Similar to the bone-
formation parameters, PTH treatment increased CFU-F numbers
in WT and Pth
–/– pups, with a lesser increase in Pth
–/–CaR
–/– pups.
The percentage increase in these osteogenic parameters was
1062 Journal of Bone and Mineral Research SHU ET AL.Fig. 2. Effects of dietary calcium and exogenous PTH on bone growth, BMD, and bone volume in Pth
–/– and Pth
–/–CaR
–/– pups. (A) X-rays of tibias, (B) the
lengths of tibias, (C) BMD values, (D) representative longitudinal sections of the proximal ends of tibias by mCT and 3D reconstruction, and (E) trabecular
bone volume (BV/TV) that were determined in the metaphyseal regions, including both primary and secondary spongiosa, of tibias from 3-week-old WT,
Pth
–/–, and Pth
–/–CaR
–/– pups fed by dams on normal Ca or high Ca or were administered exogenous PTH(1–34). Each value is the mean SEM of
determinations in 5 mice of each genotype.
 p<.05;
  p<.01;
   P<.001 compared with WT littermates of the same group;
~p<.05;
~~p<.01;
~~~p<.001 compared with Pth
–/– pups of the same group;
#p<.05;
##p<.01;
###p<.001 compared with the genotype-matched pups fed by dams on
the normal diet.
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high-calcium diet in both WT and Pth
–/– pups (Fig. 5A–D).
Effects of dietary calcium and exogenous PTH on
osteoclastic bone resorption in Pth
–/– and
Pth
–/–CaR
–/– pups
To determine whether alterations in osteoclast function also
contribute to decreased bone volume in Pth
–/– and Pth
–/–CaR
–/–
pups, osteoclast number and surface were determined by
histomorphometric analysis on TRACP-stained sections (Fig. 6).
We also examined the expression levels of Rankl and Opg mRNA
in bony tissues by real-time RT-PCR and calculated the ratio of
Rankl/Opg. The number and surfaces of TRACP
þ osteoclasts and
the ratio of Rankl/Opg were reduced significantly in Pth
–/– pups
and less significantly in Pth
–/–CaR
–/– pups compared with WT
pups fed by dams on either the normal or the high-calcium diet.
Fig. 3. Effects of dietary calcium and exogenous PTH on osteoblastic bone formation in Pth
–/– and Pth
–/–CaR
–/– pups. Representative micrographs of
sections that were (A) stained with H&E, (B) immunostained for type 1 collagen (Col I), or (C) double calcein labeled from trabecular bone from 3-week-old
WT,Pth
–/–,andPth
–/–CaR
–/–pupsfedbydamsfedwithnormalCaorhighCaorpupsthatwereadministeredexogenousPTH(1–34).ScalebarsinA,B,andC
represent 50, 50, and 25mm, respectively. (D) Numbers of osteoblasts per square millimeter (N.Ob/T.Ar, n/mm
2) that were counted in the metaphyseal
regionsofH&E-stainedtibialsectrions,(E)thetype1collagen–positiveareaasapercentageofthetissueareawasmeasuredinthemetaphysealregionsof
tibial sections, and (F) MAR of trabecular bone. Each value is the mean SEM of determinations in 5 mice of each genotype.
 p<.05;
  p<.01;
   p<.001
compared with WT littermates of the same group;
~p<.05;
~~p<.01;
~~~p<.001 compared with Pth
–/– pups of the same group;
#p<.05;
##p<0.01;
###p<.001 compared with the genotype-matched pups fed by dams on the normal diet.
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–/–
pups but did not decrease significantly in Pth
–/–CaR
–/– pups fed
by dams on the high-calcium diet compared with genotype-
matchedpupsfedbydamsonthenormaldiet.Theseparameters
increased significantly in PTH-treated WT and Pth
–/– pups and
lesssignificantlyinPTH-treatedPth
–/–CaR
–/–pupscomparedwith
vehicle-treated genotype-matched pups fed by dams on the
normal diet (Fig. 6A–D).
Effect of CaR deficiency on osteoprogenitor intracellular
signaling, intestinal calcium transporter expression, and
urinary calcium excretion
To determine whether bone marrow MSCs from CaR-deficient
micerespondtosignalingchangesinextracellularcalcium(Ca
2þ)
concentrations, cells were treated with either a high concentra-
tion of Ca
2þ or with the nonpermeant CaR agonist gadolinium
(Gd
3þ), and ERK1/2 phosphorylation was determined by Western
blots with an antibody against the active, phosphorylated form
of ERK1/2. Basal levels of ERK1/2 in the presence of 0.5mM Ca
2þ
were significantly lower in cells from CaR
–/– mice than in cells
from WT mice. Elevated Ca
2þ or Gd
3þ treatment significantly
induced ERK1/2 activation in the bone marrow MSCs from both
WT and CaR
–/– mice at 5minutes. However, the high-Ca
2þ-
induced ERK1/2 activation was markedly more pronounced in
bone marrow MSCs from WT mice than from CaR
–/– mice.
The Gd
3þ-induced ERK1/2 activation in bone marrow MSCs from
WT mice was even more pronounced than in cells from CaR
–/–
mice, where Gd
3þ-stimulated ERK1/2 activation barely reached
the basal levels of the WT mice (Fig. 7A, B). High-Ca
2þ-induced
ERK1/2 activation was time-dependent in the cells from both
WT and CaR
–/– mice. However, ERK1/2 activation from 2 to
10minutes was more markedly stimulated by 5mM Ca
2þ in cells
from WT mice than in cells from CaR
–/– mice (Fig. 7C, D).
To determine whether the ability of Ca
2þ transport in the
duodenum is altered in the CaR-deficient mice, the expression of
intestinal calcium transporters was examined in duodenums
from WT and CaR
–/– mice by Western blots. The results revealed
that protein expression levels of TRPV5, calbindin-D28K, calbin-
din-D9K, and NCX1 in the duodenum were reduced in CaR
–/–
mice compared with their WT littermates (Fig. 7E, F). When urine
calcium and creatinine levels were measured and the urine
calcium/creatinine ratio was calculated, we found that the urine
calcium/creatinineratiowaslowerinCaR
–/–micethanintheirWT
littermates (Fig. 7G).
Discussion
We employed a genetic approach to determine whether
deficiency of PTH alone or in combination with loss of CaR
Fig. 4. Effects of dietary calcium and exogenous PTH on the expression of osteoblastic genes in Pth
–/– and Pth
–/–CaR
–/– pups. Real-time RT-PCR was
performed on extracts of bone tissue from long bones of WT, Pth
–/–, and Pth
–/–CaR
–/– pups that were fed by dams on normal Ca or high Ca or were
administered exogenous PTH(1–34) for the gene expression of (A) Cbfa-1,(B) Alp, (C) type 1 collagen (ColI), and (D) osteocalcin (Ocn) as described in
‘‘Materials and Methods.’’ Messenger RNA expression, assessed by real-time RT–PCR analysis, is calculated as a ratio to the GAPDH mRNA level and
expressed relative to levels in WT mice. Each value is the mean SEM of determinations in 5 mice of each genotype.
 p<.05;
  p<.01;
   p<.001
compared with WT littermates of the same group;
~p<.05;
~~p<.01;
~~~p<.001 compared with Pth
–/– pups of the same group;
#p<.05;
##p<.01;
###p<.001 compared with the genotype-matched pups fed by dams on the normal diet.
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neonatalanimalsinvivo,andweinvestigatedtheinvolvementof
dietary calcium supplementation or exogenous PTH adminis-
tration in these processes using Pth
–/– and Pth
–/–CaR
–/– pups fed
by dams on a normal or a high-calcium diet. We demonstrated
that deletion of both PTH and CaR in suckling neonates leads to
more severe defects in skeletal development and osteoblastic
boneformationthaninpupswithdeletionofPTHalone.Thusthe
length of long bones; BMD values; trabecular volume; osteoblast
number; type 1 collagen deposition in the bone matrix; mineral
apposition rate; and gene expression of Cbfa-1, Alp, type 1
collagen, and osteocalcin, as well as CFU-F forming efficiency
from ex vivo bone marrow cultures, all were diminished more
dramatically in Pth
–/–CaR
–/– pups than Pth
–/– pups. Thus ablation
of exon 5 ofthe CaR gene, encoding a portion ofthe extracellular
domain of CaR, results in impairment in skeletal development
and osteoblastic bone formation, suggesting that the CaR is
essential for normal neonatal bone development and bone
formation in vivo. A previous study did not find any obvious
abnormalities in the cartilage and bone of adult Pth
–/–CaR
–/–
mice,
(16) and it has been suggested that an alternatively spliced
form of the CaR transcript, lacking exon 5, may compensate for
loss of the full-length CaR in adult mice with knockout of exon 5
of the receptor. This alternatively spliced CaR transcript is
generated in the growth plate,
(37) skin,
(38) and kidney
(38) of these
mice and potentially could explain these earlier observa-
tions.
(16,39) However, whether this is a partial or full compensa-
tion has not been established. Our results demonstrate that this
compensation is not full, at least under the conditions studied
here, which differ greatly, however, from those in the prior
studies. The very modest ERK1/2 activation by extracellular
calciuminbonemarrowMSCsofCaR
–/–miceisconsistentwithat
most a partially responsive CaR in skeletal cells, and the
decreased urine calcium excretion found in the CaR
–/– mice is
consistent with the loss of renal function of the CaR. Never-
theless, although the skeletal defects observed in our mouse
models appeared to be mainly due to the deficiency of CaR
function in bone-related cells, defective CaR functions in the
Fig. 5. Effects of dietary calcium andexogenous PTH on osteoprogenitor commitment in Pth
–/– and Pth
–/–CaR
–/– pups. Bone marrow cells from WT, Pth
–/–,
and Pth
–/–CaR
–/– pups that were fed by dams on normal Ca or high Ca or were administered exogenous PTH(1–34) were cultured in osteogenic
differentiation medium for 18 days and (A) stained with methylene blue for total number of colonies (CFU-F) or (B) cytochemically for ALP. (C) Total CFU-F
number per dish. (D) ALP
þ CFU-F (CFU-FAP) number per dish. Each value is the mean SEM of determinations in 5 mice of each genotype.
 p<0.05;
  p<.01;
   p<.001 compared with WT littermates of the same group;
~p<.05;
~~p<.01;
~~~p<.001 compared with Pth
–/– pups of the same group;
#p<.05;
##p<.01;
###p<.001 compared with the genotype-matched pups fed by dams on the normal diet.
1066 Journal of Bone and Mineral Research SHU ET AL.kidney and possibly in the gut also may contribute significantly
to the development of the bone phenotype in vivo.
We further investigated whether CaR deficiency affects
skeletal responses to dietary calcium supplementation. Because
the calcium source for suckling neonates is maternal milk, we
altered the dietary content of the dams to improve calcium
intake in the neonates. Our results show that a high-calcium diet
increases the calcium levels in milk of the lactating mothers. In
contrast, milk PTHrP and 1,25(OH)2D3 levels were reduced in
dams fed the high-calcium diet compared with dams fed the
normal calcium diet. Previous study has shown that the CaR
stimulates calcium transport into milk and inhibits PTHrP
secretion by the breast.
(40) In view of the fact that the protein
levels in milk were not substantially different, dietary calcium
appeared to influence milk calcium independent of changes in
protein. We also demonstrate that serum calcium, phosphorus,
PTH, and 1,25(OH)2D3 levels are altered in sucking pups by
altering the calcium in the diet of the lactating mothers. These
results suggest that the high-calcium diet can elevate milk
calcium significantly in lactating mothers, which subsequently
results in changes of serum ion homeostasis and calcitrophic
hormones in suckling neonates. These findings are consistent
with our previous report related to the effect of dietary calcium
supplementation on milk calcium content and calcium-regulat-
ing hormones in dams and on serum calcium, phosphorus, and
1,25(OH)2D3 in suckling pups.
(28)
We found that the loss of CaR in Pth
–/–CaR
–/– pups abolished
dietary calcium supplement–mediated augmentation of osteo-
blastic bone formation. Thus, compared with genotype-matched
pups fed by dams on the normal diet, skeletal growth and bone-
formation parameters were increased in the WT and Pth
–/– pups
but not in Pth
–/–CaR
–/– pups fed by dams on the high-calcium
diet. These results, demonstrating that CaR deficiency in vivo
abolishes skeletal responses to dietary calcium supplementation
in suckling neonates, are consistent with previously published
in vitro findings in which exposure of primary osteoblasts or a
variety of osteoblast-like cells to high calcium or the polycationic
CaR agonists neomycin and gadolinium stimulates their
Fig. 6. EffectsofdietarycalciumandexogenousPTH(1–34)onosteoclasticboneresorptioninPth
–/–andPth
–/–CaR
–/–pups.Representativemicrographsof
sectionsofthetibiasfromWT,Pth
–/–,andPth
–/–CaR
–/–pupsthatwerefedbydamsonnormalCaorhighCaorwereadministeredexogenousPTH(1–34)(A)
stained histochemically for TRACP. Scale bar¼50mm. (B) Number of TRACP
þ osteoclasts related to tissue area (N.Oc/T.Ar, n/mm
2) and (C) osteoclast
surface relative to bone surface (Oc.S/BS, %) were counted in the metaphyseal regions of TRACP-stained tibial sections. (D) Real-time RT-PCR was
performed on bone extracts for Rankl and Opg mRNA as described in ‘‘Materials and Methods.’’ Messenger RNA expression assessed by real-time RT-PCR
analysis is calculated as a ratio to the GAPDH mRNA level and expressed relative to levels of WT mice. Ratio of Rankl/Opg relative mRNA levels was
calculated. Each value is the mean SEM of determinations in 5 mice of each group.
 p<.05;
  p<.01;
   p<.001 compared with WT littermates of the
same group;
~p<.05;
~~p<.01;
~~~p<.001 compared with Pth
–/– pups of the same group;
#p<.05;
##p<.01;
###p<.001 compared with the
genotype-matched pups fed by dams on the normal diet.
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p42/44 MAPK, p38 MAPK, and/or JNK pathways.
(5,7,41,42)
Although an alternate skeletal calcium receptor, GPRC6A, has
been described
(43,44) through which calcium might act, its role in
skeletal physiology is unclear because conflicting reports on the
skeletal phenotype of Gprc6a null mice have been reported,
(44,45)
andnocalciumchannelortransporterinbonehasbeenreported
consistently to alter osteoblast and osteoclast activity in
response to changes in serum calcium. Consequently, the
calcium effect appears to be via CaR. Although serum calcium
Fig. 7. Effect of CaR deficiency on osteoprogenitor intracellular signaling, intestinal calcium transporter expression, and renal calcium excretion. (A)
Second-passaged bone marrow MSCs from WT and CaR
–/– (KO) mice were treated with 0.5 and 5mM CaCl2 or 50mMG d
3þ for 5minutes, and cells were
analyzed by Western blot for ERK phosphorylation activation (p-ERK) and total ERK (ERK). (B) p-ERK level relative to total ERK level was assessed by
densitometric analysis and expressed relative to levels of cells from WT mice treated with 0.5mM CaCl2.( C) The cells were treated with 5mM CaCl2 for
various times and were analyzed by Western blot for ERK phosphorylation activation (p-ERK) and total ERK (ERK). (D) p-ERK level relative to total ERK level
was assessed by densitometric analysis and expressed relative to levels of cells from untreated cultures. (E) Western blots of extracts of duodenums from
WT and CaR
–/– (KO) mice for expression of TRPV5, calbindin-D28K (CB28K), calbindin-D9K (CB9K), and NCX1. b-Tubulin was used as a loading control for
Western blots. (F) TRPV5, CB28K, CB9K and NCX protein levels relative to b-tubulin protein level were assessed by densitometric analysis and expressed
relative to levels of WT mice. (G) Urine calcium and urine creatinine were measured as described in ‘‘Materials and Methods,’’ and the urine calcium/
creatinine ratio was calculated.
 p<.05;
  p<.01;
   p<.001 compared with WT mice.
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–/–CaR
–/– mice than in the
WT and Pth
–/– mice, our conclusion would be that even if serum
calcium were elevated to the same degree in all phenotypes
we employed in this study, the absence of the CaR would be
the factor reducing skeletal responsiveness. Our results therefore
strongly indicate that CaR plays an important role in mediating
dietary calcium-induced changes in both bone formation and
resorption.in neonates in vivo.
We demonstrated previously that the skeletal anabolic action
of PTH in neonates results not only from its direct action via the
PTH receptor to increase the osteoblast pool but also by an
indirect action mediated through increasing extracellular
calcium concentration.
(28) In this study, we further demonstrated
that increasing the extracellular calcium concentration acts
cooperatively with PTH to promote osteoblastic bone formation
in the neonate and that the effect of the former is mediated via
theCaR.When1-week-oldWT,Pth
–/–,andPth
–/–CaR
–/–pupswere
injected with PTH(1–34) daily for 2 weeks, PTH(1–34) adminis-
trationraised serumcalcium and 1,25(OH)2D3levels andreduced
serum phosphorus levels significantly in WT and Pth
–/– pups and
less significantly in Pth
–/–CaR
–/– pups. The length of long bones;
BMD values; trabecular volume; osteoblast number; type 1
collagen deposition in bone matrix; MAR; and the gene
expression of Cbfa-1, Alp, type 1 collagen, and osteocalcin,a s
well as CFU-F forming potential from ex vivo bone marrow
cultures, all were increased significantly in WT and Pth
–/– pups
and less significantly in Pth
–/–CaR
–/– pups. Thus it is likely that the
CaR is required for an optimal skeletal anabolic action of PTH in
neonates.
Previousstudieshaverevealedtheimportanceofregulationof
osteoclastfunctionbyextracellularcalcium.Exposingosteoclasts
toveryhighcalcium,asseenonlyinthebonemicroenvironment,
results in dramatic cell retraction followed by a profound
inhibition of bone resorption.
(46-49) It has been shown that such
very high calcium levels inhibit bone-resorbing activity of
osteoclasts by directly acting on the CaR, which is expressed by
osteoclast precursors
(6) and mature osteoclasts.
(10,11) Further-
more, mature osteoclasts undergo apoptosis in the presence of
very high calcium, and a dominant-negative CaR construct
abrogates this effect, indicating the role of CaR in osteoclast
apoptosis. The signaling pathways that are associated with
induction of osteoclast apoptosis by the CaR likely involve PLC
and NF-kB. Evidence also has been provided recently to support
the role of CaR in osteoclast differentiation, and using CaR
–/–
mice, Mentaverri and colleagues
(11) have shown that osteoclast
differentiation from bone marrow precursor cells in vitro is 70%
less in CaR
–/– mice compared with WT mice. Taken together,
these studies suggest that CaR activation is linked to physiologic
responses of both enhanced differentiation and inhibition of
bone-resorbing activity, although it is not clear if the calcium
concentrations required for these processes are equivalent. In
this study, we found that TRACP
þ osteoclast numbers and
surfaces, as well as the ratio of Rankl/OPG, were reduced more
dramatically in Pth
–/– pups than in Pth
–/–CaR
–/– pups fed by dams
on the normal diet and, unlike pups from dams fed a high-
calcium intake, were not further reduced significantly in
Pth
–/–CaR
–/– pups fed by dams on the same diet. Taken together,
our observations suggest that in the model used, CaR is needed
to support the calcemic action of PTH and to mediate calcium-
induced inhibition of osteoclastic bone resorption, as suggested
by earlier studies.
(11)
Our findings are relevant to neonates but may differ in adult
CaR-deficient mice. Thus our previous studies had shown that
thebonephenotypesofPth
–/–micearedifferentbeforeandafter
weaning. Trabecular bone volume was reduced significantly in
newborn and 2- and 3-week-old Pth
–/– pups compared with their
WT littermates.
(28,29,36) In contrast, trabecular bone volume was
increased significantly in 4-month-old Pth
–/– mice compared
with their WT littermates.
(32,34) Although it is unclear why PTH
deficiency results in such different bone phenotypes before
weaning and in adulthood, such changes may be related to the
different forms of food intake in these two settings. Mice are
breast-fed before weaning but eat mouse chow thereafter.
Breast milk not only contains a higher calcium concentration
than the normal diet fed after weaning but also contains low
levels of 1,25(OH)2D3,
(28) both of which will have an impact on
intestinal calcium absorption. Physiologic adaptation to these
environmental changes may involve alterations in the function
and/or efficacy of calcium-regulating hormones, including PTH,
vitamin D, and calcium.
In summary, this study describes the role of the CaR in skeletal
turnover in neonates and for the first time demonstrates that in
the neonate, the CaR is essential to mediate changes in bone
turnoverresultingfromalterationsindietarycalciumaswellasto
facilitate the increased bone turnover elicited by PTH.
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